Open Access

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors

  • Authors:
    • Yosuke Miura
    • Kyoichi Kaira
    • Reiko Sakurai
    • Hisao Imai
    • Yoshio Tomizawa
    • Noriaki Sunaga
    • Koichi Minato
    • Takeshi Hisada
    • Tetsunari Oyama
    • Masanobu Yamada
  • View Affiliations

  • Published online on: June 19, 2017     https://doi.org/10.3892/ol.2017.6419
  • Pages: 2369-2378
  • Copyright: © Miura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Class III β-tubulin (TUBB3) and Topoisomerase-II (topo-II) are considered to be the predictors of therapeutic efficacy and outcome in several types of human neoplasm. However, whether TUBB3 or topo‑II may predict the response to combination chemotherapy and prognosis in patients with advanced thymic carcinoma (ATC) remains unclear. The aim of the present study was to investigate the prognostic significance of TUBB3 and topo‑II expression levels in ATC. A total of 34 patients with ATC who received combination chemotherapy were enrolled in the present study. Immunohistochemical analysis was used to examine the expression of TUBB3, topo‑II and Ki‑67 in tumor specimens obtained by surgical resection or biopsy. TUBB3 and topo‑II were highly expressed in 38 and 53% of the tumors, respectively. Progression‑free survival (PFS) was significantly shorter in patients with high levels of TUBB3 compared with those with low levels of TUBB3 (P<0.01), whereas no significant difference in PFS between patients with high and low topo‑II expression levels was observed (P=0.31). Patients with overexpression of TUBB3 or topo‑II exhibited significantly shorter overall survival rates (OS) compared with those patients with low levels of expression of these proteins (TUBB3; P=0.01, topo‑II; P=0.01). Multivariate analysis demonstrated that a high level of TUBB3 expression was an independent unfavorable prognostic factor for OS, and a high level of topo‑II expression tended to correlate with poor prognosis without statistical significance. Additionally, a subset analysis demonstrated that the treatment with taxanes, but not topo‑II inhibitors, tended to prolong OS in patients with TUBB3 overexpression and there was significant survival advantage of chemoradiotherapy over chemotherapy in patients with topo‑II overexpression. It was revealed that an enhanced expression of TUBB3 or topo‑II was clearly associated with clinical outcomes in patients with ATC who received combination chemotherapy, including taxanes or topo‑II inhibitors, suggesting the prognostic significance of these markers.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M, Yamada M, et al: Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncol Lett 14: 2369-2378, 2017
APA
Miura, Y., Kaira, K., Sakurai, R., Imai, H., Tomizawa, Y., Sunaga, N. ... Yamada, M. (2017). Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncology Letters, 14, 2369-2378. https://doi.org/10.3892/ol.2017.6419
MLA
Miura, Y., Kaira, K., Sakurai, R., Imai, H., Tomizawa, Y., Sunaga, N., Minato, K., Hisada, T., Oyama, T., Yamada, M."Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors". Oncology Letters 14.2 (2017): 2369-2378.
Chicago
Miura, Y., Kaira, K., Sakurai, R., Imai, H., Tomizawa, Y., Sunaga, N., Minato, K., Hisada, T., Oyama, T., Yamada, M."Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors". Oncology Letters 14, no. 2 (2017): 2369-2378. https://doi.org/10.3892/ol.2017.6419